{
    "id": 29007,
    "fullName": "CTRC - NTRK1",
    "impact": "fusion",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "CTRC-NTRK1 results from the fusion of CTRC and NTRK1 (PMID: 29466156). CTRC-NTRK1 has been identified in pancreatic cancer (PMID: 29466156), but has not been biochemically characterized and therefore, the effect on protein function is unknown (PubMed, Nov 2019).",
            "references": [
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                },
                {
                    "id": 10867,
                    "pubMedId": 29466156,
                    "title": "Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29466156"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 11330,
        "geneSymbol": "CTRC",
        "terms": [
            "CTRC",
            "CLCR",
            "ELA4"
        ]
    },
    "variant": "CTRC - NTRK1",
    "createDate": "11/27/2018",
    "updateDate": "11/08/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 4914,
                "geneSymbol": "NTRK1",
                "terms": [
                    "NTRK1",
                    "MTC",
                    "p140-TrkA",
                    "TRK",
                    "Trk-A",
                    "TRK1",
                    "TRKA"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 15295,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In Phase II trials, Vitrakvi (larotrectinib) treatment resulted in partial response in a patient with pancreatic cancer harboring an CTRC-NTRK1 fusion (PMID: 29466156; NCT02122913, NCT02637687, NCT02576431).",
            "molecularProfile": {
                "id": 30930,
                "profileName": "CTRC - NTRK1"
            },
            "therapy": {
                "id": 2650,
                "therapyName": "Larotrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10867,
                    "pubMedId": 29466156,
                    "title": "Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29466156"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15270,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, NTRK1 A608D was identified at disease progression in a patient with pancreatic cancer harboring CTRC-NTRK1 treated with Vitrakvi (larotrectinib) (PMID: 29466156; NCT02122913, NCT02637687, NCT02576431).",
            "molecularProfile": {
                "id": 30931,
                "profileName": "CTRC - NTRK1 NTRK1 A608D"
            },
            "therapy": {
                "id": 2650,
                "therapyName": "Larotrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 10867,
                    "pubMedId": 29466156,
                    "title": "Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29466156"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19083,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a patient-derived xenograft (PDX) model with pancreatic cancer harboring CTRC-NTRK1, BRAF V600E, and KRAS G12D demonstrated greater tumor growth inhibition when treated with a combination of Tafinlar (dabrafenib), Mekinist (trametinib), and Vitrakvi (larotrectinib) versus a combination of Tafinlar (dabrafenib) and Mekinst (trametinib) only (PMID: 31406350).",
            "molecularProfile": {
                "id": 33509,
                "profileName": "CTRC - NTRK1 BRAF V600E KRAS G12D"
            },
            "therapy": {
                "id": 8908,
                "therapyName": "Dabrafenib + Larotrectinib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16397,
                    "pubMedId": 31406350,
                    "title": "Resistance to TRK inhibition mediated by convergent MAPK pathway activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31406350"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18709,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with pancreatic cancer harboring CTRC-NTRK1, BRAF V600E, and KRAS G12D demonstrated resistance to treatment with LOXO-195 (PMID: 31406350).",
            "molecularProfile": {
                "id": 33509,
                "profileName": "CTRC - NTRK1 BRAF V600E KRAS G12D"
            },
            "therapy": {
                "id": 5917,
                "therapyName": "LOXO-195",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 16397,
                    "pubMedId": 31406350,
                    "title": "Resistance to TRK inhibition mediated by convergent MAPK pathway activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31406350"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19082,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with pancreatic cancer harboring CTRC-NTRK1 and BRAF V600E treated with a combination of Tafinlar (dabrafenib) and Mekinist (trametinib) demonstrated tumor regression, but later showed radiographical progression and was found to have acquired KRAS G12D (PMID: 31406350).",
            "molecularProfile": {
                "id": 33509,
                "profileName": "CTRC - NTRK1 BRAF V600E KRAS G12D"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 16397,
                    "pubMedId": 31406350,
                    "title": "Resistance to TRK inhibition mediated by convergent MAPK pathway activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31406350"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18708,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with pancreatic cancer harboring CTRC-NTRK1 progressed on Vitrakvi (larotrectinib) treatment, showing acquisition of BRAF V600E via biopsy testing and BRAF V600E and KRAS G12D via cell-free DNA testing (PMID: 31406350).",
            "molecularProfile": {
                "id": 33509,
                "profileName": "CTRC - NTRK1 BRAF V600E KRAS G12D"
            },
            "therapy": {
                "id": 2650,
                "therapyName": "Larotrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 16397,
                    "pubMedId": 31406350,
                    "title": "Resistance to TRK inhibition mediated by convergent MAPK pathway activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31406350"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19130,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination therapy of Vitrakvi (larotrectinib) and Mekinist (trametinib) resulted in delayed tumor growth in a Vitrakvi (larotrectinib)-resistant patient-derived xenograft (PDX) model with pancreatic cancer harboring CTRC-NTRK1 and BRAF V600E, but led to controlled tumor growth for 1 month and tumor regression at 3 months in the PDX model with only CTRC-NTRK1, which subsequently revealed a low variant allele frequency for BRAF V600E (PMID: 31406350).",
            "molecularProfile": {
                "id": 33936,
                "profileName": "CTRC - NTRK1 BRAF V600E"
            },
            "therapy": {
                "id": 8918,
                "therapyName": "Larotrectinib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16397,
                    "pubMedId": 31406350,
                    "title": "Resistance to TRK inhibition mediated by convergent MAPK pathway activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31406350"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 30930,
            "profileName": "CTRC - NTRK1",
            "profileTreatmentApproaches": [
                {
                    "id": 19346,
                    "name": "Larotrectinib",
                    "profileName": "CTRC - NTRK1"
                }
            ]
        },
        {
            "id": 30931,
            "profileName": "CTRC - NTRK1 NTRK1 A608D",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 33509,
            "profileName": "CTRC - NTRK1 BRAF V600E KRAS G12D",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 33936,
            "profileName": "CTRC - NTRK1 BRAF V600E",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}